总市值

Search documents
澳洋健康收盘下跌1.63%,滚动市盈率114.10倍,总市值32.31亿元
Sou Hu Cai Jing· 2025-08-12 08:38
Company Overview - Aoyang Health's closing price on August 12 was 4.22 yuan, down 1.63%, with a rolling PE ratio of 114.10 times and a total market value of 3.231 billion yuan [1] - The company operates in the medical services, pharmaceutical distribution, and biotechnology sectors, with main products including medical services and pharmaceutical logistics [1] - As of March 31, 2025, Aoyang Health had 53,714 shareholders, a decrease of 3,624 from the previous period, with an average holding value of 352,800 yuan and an average holding of 27,600 shares per shareholder [1] Financial Performance - In the first quarter of 2025, Aoyang Health reported revenue of 452 million yuan, a year-on-year decrease of 22.27%, and a net profit of 18.4992 million yuan, down 39.82% year-on-year, with a gross margin of 15.09% [2] - The company's PE ratio (TTM) is 114.10, while the industry average is 48.17 and the industry median is 63.54 [2] Industry Comparison - Aoyang Health ranks 39th in the medical services industry based on PE ratio, which has an average of 48.17 and a median of 63.54 [1] - The company has been recognized in various awards, including being ranked 32nd in the non-public hospital top 100 list and 2nd among county-level non-public hospitals in China [1]
奕瑞科技收盘上涨5.79%,滚动市盈率39.92倍,总市值187.20亿元
Sou Hu Cai Jing· 2025-08-11 12:02
Core Viewpoint - Yirui Technology's stock closed at 93.5 yuan, up 5.79%, with a rolling PE ratio of 39.92, marking a new low in 39 days, and a total market value of 18.72 billion yuan [1] Company Summary - Yirui Technology specializes in the research, production, sales, and service of digital X-ray detectors, high-voltage generators, combination ray sources, and tubes [1] - The main products include the universal series, dental series, mammography series, radiotherapy series, industrial series, high-voltage generators, and combination ray sources [1] - As of the first quarter of 2025, the company reported operating revenue of 482 million yuan, a year-on-year decrease of 1.92%, and a net profit of 143 million yuan, a year-on-year increase of 2.74%, with a gross profit margin of 48.92% [1] Industry Summary - The average PE ratio for the medical device industry is 56.56, with a median of 39.76, placing Yirui Technology at 77th in the industry ranking [1] - As of the first quarter of 2025, 51 institutions hold shares in Yirui Technology, with a total of 17.0041 million shares valued at 1.49 billion yuan [1] - The industry average market value is 11.897 billion yuan, while the median market value is 5.767 billion yuan [2]
安图生物收盘上涨3.39%,滚动市盈率21.22倍,总市值241.94亿元
Sou Hu Cai Jing· 2025-08-11 11:38
Core Viewpoint - Antu Biology's stock closed at 42.34 yuan, up 3.39%, with a rolling PE ratio of 21.22, marking a new low in 88 days, and a total market capitalization of 24.194 billion yuan [1] Company Summary - Antu Biology specializes in the research, manufacturing, integration, and service of in vitro diagnostic reagents and instruments, with key products including immunodiagnostic reagents, microbiological testing reagents, molecular diagnostic reagents, biochemical reagents, and instruments [1] - As of March 31, 2025, the number of shareholders reached 34,163, an increase of 3,382 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] - The latest quarterly report for Q1 2025 shows revenue of 996 million yuan, a year-on-year decrease of 8.56%, and a net profit of 270 million yuan, down 16.76%, with a gross profit margin of 65.07% [1] Industry Summary - The average PE ratio for the medical device industry is 56.56, with a median of 39.76, placing Antu Biology at 45th in the industry ranking [1] - The industry average market capitalization is 118.97 billion yuan, while the median is 57.67 billion yuan [2]
华电国际收盘下跌1.10%,滚动市盈率10.22倍,总市值590.04亿元
Sou Hu Cai Jing· 2025-08-11 10:43
Company Overview - Huadian International's closing price on August 11 was 5.41 yuan, down 1.10%, with a rolling PE ratio of 10.22 times and a total market capitalization of 59.004 billion yuan [1] - The company's main business includes power generation, heating, coal sales, and other related services, with electricity and heat products as its primary offerings [1] Financial Performance - For the first quarter of 2025, Huadian International reported operating revenue of 26.577 billion yuan, a year-on-year decrease of 14.14%, and a net profit of 1.930 billion yuan, a year-on-year increase of 3.66%, with a gross profit margin of 10.73% [1] Industry Comparison - The average PE ratio for the power industry is 23.07 times, with a median of 19.67 times, placing Huadian International at 15th in the industry ranking [1] - The company has a total of 57 institutional holders, including 57 funds, with a combined holding of 162.4649 million shares valued at 0.889 billion yuan [1] Valuation Metrics - Huadian International's PE (TTM) is 10.22, while the industry average is 23.07, indicating a significant undervaluation compared to peers [2] - The company's price-to-book ratio is 1.33, compared to the industry average of 2.17 [2]
五洲医疗收盘上涨1.19%,滚动市盈率81.02倍,总市值28.94亿元
Sou Hu Cai Jing· 2025-08-11 10:25
8月11日,五洲医疗今日收盘42.56元,上涨1.19%,滚动市盈率PE(当前股价与前四季度每股收益总和 的比值)达到81.02倍,创480天以来新低,总市值28.94亿元。 从行业市盈率排名来看,公司所处的医疗器械行业市盈率平均56.56倍,行业中值39.76倍,五洲医疗排 名第101位。 股东方面,截至2025年7月31日,五洲医疗股东户数7255户,较上次增加848户,户均持股市值35.28万 元,户均持股数量2.76万股。 安徽宏宇五洲医疗器械股份有限公司的主营业务是一次性使用无菌输注类医疗器械的研发、制造和销 售,以及其他诊断、护理等相关医疗用品的集成供应。公司的主要产品是注射器、安全型注射器、胰岛 素注射器、配药注射器、输液器、输血器、注射针、静脉输液针、采血针、胰岛素注射笔用针头、安全 注射针、安全采血针、血压表、面罩。 最新一期业绩显示,2025年一季报,公司实现营业收入1.04亿元,同比15.59%;净利润563.45万元,同 比-43.00%,销售毛利率14.62%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13五洲医疗81.0272.413.7728.94亿行业平均 56. ...
三星医疗收盘上涨4.56%,滚动市盈率13.91倍,总市值331.78亿元
Sou Hu Cai Jing· 2025-08-08 12:05
Core Viewpoint - Samsung Medical's stock price increased by 4.56% to 23.61 yuan, with a rolling PE ratio of 13.91, marking a new low in 55 days, and a total market capitalization of 33.178 billion yuan [1][2] Company Summary - Samsung Medical's main business segments include smart power distribution and medical services, with key products such as smart meters, high-end gateway meters, smart terminals, power boxes, communication modules, and various integrated solutions [1] - The company has received multiple accolades, including being recognized as a national-level intellectual property demonstration enterprise and a provincial key enterprise research institute [1] Financial Performance - For the first quarter of 2025, Samsung Medical reported revenue of 3.631 billion yuan, a year-on-year increase of 20.03%, and a net profit of 489 million yuan, reflecting a year-on-year growth of 34.33% [2] - The company's gross profit margin stands at 28.90% [2] Industry Comparison - In the electric grid equipment industry, Samsung Medical's PE ratio of 13.91 is significantly lower than the industry average of 38.47 and the median of 41.87 [2] - The company ranks 34th in terms of PE ratio within its industry [1]
西山科技收盘上涨1.94%,滚动市盈率39.18倍,总市值33.01亿元
Sou Hu Cai Jing· 2025-08-08 12:04
Company Overview - Xishan Technology's closing price on August 8 was 72.56 yuan, up 1.94%, with a rolling PE ratio of 39.18, marking a new low in 207 days, and a total market capitalization of 3.301 billion yuan [1] - The company operates in the surgical medical device sector, focusing on the research, manufacturing, sales, and service of surgical instruments, including surgical power devices, endoscopic systems, and energy surgical equipment [1] Financial Performance - For the first quarter of 2025, Xishan Technology reported revenue of 65.8771 million yuan, a year-on-year decrease of 11.20%, and a net profit of 11.4768 million yuan, down 55.66% year-on-year, with a gross profit margin of 67.64% [1] Industry Comparison - The average PE ratio for the medical device industry is 55.70, with a median of 39.08, placing Xishan Technology at the 77th position in the industry ranking [1] - The company’s static PE ratio is 33.46, and its price-to-book ratio is 1.91 [2]
南微医学收盘下跌2.65%,滚动市盈率27.81倍,总市值158.73亿元
Sou Hu Cai Jing· 2025-08-08 11:33
Group 1 - The core viewpoint of the articles highlights the performance and valuation of Nanwei Medical, which has a current stock price of 84.5 yuan and a rolling PE ratio of 27.81 times, significantly lower than the industry average of 55.70 times [1][2] - As of March 31, 2025, Nanwei Medical has 13,313 shareholders, an increase of 639 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The company specializes in the research, manufacturing, and sales of minimally invasive medical devices, with key products including biopsy, hemostasis, closure devices, and various imaging systems [1] Group 2 - In the first quarter of 2025, Nanwei Medical reported a revenue of 699 million yuan, representing a year-on-year growth of 12.75%, and a net profit of 161 million yuan, also reflecting a year-on-year increase of 12.18%, with a gross margin of 65.69% [1] - The company ranks 56th in terms of PE ratio within the medical device industry, which has a median PE of 39.08 times [1][2] - The industry average PE ratio is 55.70 times, indicating that Nanwei Medical is undervalued compared to its peers [2]
洛阳钼业收盘上涨2.95%,滚动市盈率13.55倍,总市值2088.08亿元
Jin Rong Jie· 2025-08-08 11:32
Group 1 - The core viewpoint of the article highlights the performance and market position of Luoyang Molybdenum Co., Ltd., noting its stock price increase and market capitalization [1] - As of August 8, the closing stock price of Luoyang Molybdenum is 9.76 yuan, with a rise of 2.95%, and a rolling PE ratio of 13.55 times, leading to a total market value of 208.08 billion yuan [1] - The company ranks 5th in the small metals industry, which has an average PE ratio of 69.07 times and a median of 64.25 times [1] Group 2 - As of the first quarter of 2025, 212 institutions hold shares in Luoyang Molybdenum, with a total of 422.579 million shares and a market value of 3.558 billion yuan [1] - The main business of Luoyang Molybdenum includes mining and processing of base and rare metals, with key products being molybdenum, tungsten, copper, cobalt, niobium, phosphorus, and mineral metal trading [1] - The latest financial results for the first quarter of 2025 show an operating income of 46.006 billion yuan, a year-on-year decrease of 0.25%, and a net profit of 3.946 billion yuan, reflecting a year-on-year increase of 90.47%, with a gross profit margin of 22.33% [1]
拱东医疗收盘上涨3.76%,滚动市盈率30.02倍,总市值46.22亿元
Sou Hu Cai Jing· 2025-08-08 11:27
Group 1 - The core viewpoint of the articles highlights the performance and valuation of Gongdong Medical, which closed at 20.96 yuan, up 3.76%, with a rolling PE ratio of 30.02, marking a new low in 33 days, and a total market capitalization of 4.622 billion yuan [1][2] - Gongdong Medical's PE ratio is significantly lower than the industry average of 55.70 and the industry median of 39.08, ranking 58th in the medical device sector [1][2] - As of March 31, 2025, Gongdong Medical had 8,909 shareholders, an increase of 735 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - Gongdong Medical specializes in the research, production, and sales of disposable medical consumables, with key products including medical testing, blood collection, collection, medical care, and drug packaging [1] - The latest quarterly report for Q1 2025 shows Gongdong Medical achieved revenue of 264 million yuan, a year-on-year decrease of 2.74%, and a net profit of 27.41 million yuan, down 39.23%, with a gross profit margin of 32.40% [1]